Compare Globalstar (GSAT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globalstar vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Globalstar trades at $82.24 (market cap $10.71B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Globalstar is far larger — about 11× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Globalstar is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 23 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GSAT | MRVI | |
|---|---|---|
Market Cap | $10.71B | $972.90M |
Volume | 768,707 | 4,325,710 |
Sector | Media | Health |
52-Week High | $84.43 | $9.00 |
52-Week Low | $41.54 | $2.83 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $10.71B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSAT trades at $82.68, down 0.43% with a bullish technical outlook. The company shows strong gross margins at 62.25% but faces profitability challenges with negative net income margins. Recent satellite launches and infrastructure expansion in Greece signal growth potential, though earnings have consistently missed expectations.
Investment outlook remains mixed with 40% analyst buy ratings but persistent losses. Key risks include execution challenges and high valuation multiples. Positive cash flow and strategic developments provide upside catalysts, but profitability improvement is critical for sustained shareholder value.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Globalstar
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
